Biocytogen

Biocytogen is a pioneering global biotechnology company and Contract Research Organization (CRO) that drives the discovery and development of novel antibody-based therapeutics. Founded originally on advanced gene-editing technology, the company operates a powerful "dual-engine" platform that seamlessly integrates a massive library of fully human antibodies with an extensive portfolio of target-humanized animal models. Under the hood, Biocytogen utilizes its proprietary SUPCE™ gene-editing technology to engineer the RenMice® family (including RenMab®, RenLite®, and RenNano®). These specialized, highly immunodeficient mouse models (such as their flagship B-NDG™ mice) are designed to produce fully human monoclonal, bispecific, and heavy-chain antibodies, bridging the gap between animal testing and human clinical trials. Furthermore, through its sub-brand BioMice™, the company provides thousands of off-the-shelf disease models and comprehensive preclinical pharmacology services. Their primary target audience includes global pharmaceutical giants and agile biotech startups who rely on Biocytogen to systematically de-risk and accelerate their entire drug development pipeline—from initial target identification straight through to IND submission.